Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 12/20 | 0.76 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5313861 | 0.87 | LTA4H (1.00) | LTA4HLMNAGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL5312987 | 0.86 | LTA4H (0.68) | LTA4HLMNAGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL5313790 | 0.85 | LTA4H (0.59) | LTA4HLMNAGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL5660863 | 0.83 | LTA4H (1.00) | LTA4HLMNAGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL5314769 | 0.83 | LTA4H (0.80) | LTA4HLMNAGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL5312484 | 0.83 | LTA4H (0.90) | LTA4HLMNAGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL3041150 | 0.83 | LTA4H (0.68) | LTA4H | |
| SCHEMBL5314942 | 0.83 | LTA4H (0.73) | LTA4HLMNAGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL5658898 | 0.82 | LTA4H (0.79) | LTA4HLMNAGAASMN1; SMN2ALDH1A1 | |
| SCHEMBL5316003 | 0.81 | LTA4H (0.77) | LTA4HLMNAGAASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007079003-A2 | AMIDE INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-07-12 | — | — | WO | claimed |
| WO-2007079003-A2 | AMIDE INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155727-A1 | Amide inhibitors of leukotriene A4 hydrolase | SCHERING AKTIENGESSELLSCHAFT (DE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155727-A1 | Amide inhibitors of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885LMNA 1402/4885GAA 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.